Apr 24, 2023 02:11PM
Sep 13, 2022 03:22PM
Jun 30, 2022 05:33PM
Jun 10, 2021 02:34PM
Apr 6, 2020 12:30PM
Apr 6, 2020 12:20PM
Mar 27, 2020 03:53PM Onxeo Will Publish Its Annual Results on April 17, 2020
Feb 27, 2020 11:45AM
Feb 27, 2020 11:45AM
Feb 11, 2020 01:20PM
Jan 29, 2020 01:00PM
Jan 29, 2020 01:00PM
Jan 28, 2020 11:45AM
Jan 28, 2020 11:45AM Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020
Jan 20, 2020 03:19PM
Jan 20, 2020 11:57AM
Jan 6, 2020 11:45AM
Dec 9, 2019 11:45AM
Nov 13, 2019 12:00PM
Nov 5, 2019 11:45AM
Nov 4, 2019 11:45AM Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
Oct 17, 2019 12:44PM
Oct 15, 2019 12:00PM
Oct 14, 2019 12:00PM
Sep 18, 2019 12:00PM
Sep 11, 2019 11:45AM
Jul 31, 2019 01:42PM
Jul 25, 2019 01:42PM Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
Jul 3, 2019 11:47AM
Jul 1, 2019 01:00AM
Jun 20, 2019 12:30PM
Jun 7, 2019 02:00PM
May 28, 2019 12:00PM
May 22, 2019 12:00PM
May 6, 2019 12:00PM Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy
Apr 8, 2019 11:45AM
Apr 5, 2019 04:35PM
Mar 25, 2019 02:02PM
Mar 12, 2019 01:02PM
Feb 13, 2019 12:31PM
Jan 4, 2019 11:45AM
Jan 3, 2019 12:00PM Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
Dec 20, 2018 01:00PM
Dec 18, 2018 02:30PM
Dec 13, 2018 01:00PM
Dec 3, 2018 12:00PM
Nov 5, 2018 01:30AM
Oct 25, 2018 12:30PM
Oct 18, 2018 12:30PM Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019
Oct 3, 2018 11:45AM

328,694 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All